GlobeNewswire Inc.··Aligos Therapeutics, Inc.Aligos Therapeutics Cuts Losses 82% While Advancing Hepatitis B Pipeline
Aligos reports $24.2M net loss in 2025, down 82% YoY. Key hepatitis B study enrollment complete; cash runway extends to Q3 2026.
ALGSPhase 2 clinical trialfinancial results